SPONSOR
Tianjin Medical University Second Hospital
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
Conditions studied: Renal Cell Carcinoma (RCC)Solid Tumor, AdultNext-generation SequencingPrecision MedicineProstate CancerCDK12 Gene Mutation
Tianjin Medical University Second Hospital is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Renal Cell Carcinoma (RCC), Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tianjin Medical University Second Hospital
How many clinical trials has Tianjin Medical University Second Hospital sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Tianjin Medical University Second Hospital, of which 3 are actively recruiting participants. These trials cover conditions including Renal Cell Carcinoma (RCC), Solid Tumor, Adult, Next-generation Sequencing. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tianjin Medical University Second Hospital research focus on?
Tianjin Medical University Second Hospital clinical trials span Renal Cell Carcinoma (RCC), Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine, Prostate Cancer, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tianjin Medical University Second Hospital clinical trial?
To participate in a Tianjin Medical University Second Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tianjin Medical University Second Hospital trials with current recruitment status updated daily.
Clinical Trials by Tianjin Medical University Second Hospital
NCT07657325
Recruiting
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
Renal Cell Carcinoma (RCC)
NCT06895733 Phase 1, Phase 2
Recruiting
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Solid Tumor, Adult
NCT06663007 Phase 1, Phase 2
Recruiting
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Prostate Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology